膀がんにおける術後のエンフォルトゥマブ (Vedotin) とペムブロリズマブ (Pembrolizumab)
Christof Vulsteke1,2, Nabil Adra3, Pongwut Danchaivijitr4
1Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent, Belgium.
The New England journal of medicine
|February 18, 2026
まとめ
術後のエンフォルトゥマブベドチンとペンブロリズマブは,シスプラチン化学療法を受けられない筋肉侵襲性膀がん患者のイベントフリーおよび全生存期間を大幅に改善しました. この組み合わせ療法は,手術のみと比較して,病理学的完全応答率も増加させました.
科学分野:
- 腫瘍学 腫瘍学
- クリニック・トライアル 臨床試験
- 癌の治療薬について
背景:
- シスプラチン化学療法を受ける資格のない筋肉侵襲性膀がん (MIBC) の患者は,通常,急性半球切除手術を受ける.
- 術後の治療は,この特定の患者グループにおける結果を向上させるための潜在的な戦略です.
研究 の 目的:
- シスプラチン不適格MIBC患者における手術と併用されたペリオペラティブエンフォルトゥマブベドチンとペンブロリズマブの有効性と安全性を評価する.
- イベントフリー生存率,全生存率,および外科手術のみに対する病理学的完全応答率を比較するために.
主な方法:
- 3期,オープンラベル,シスプラチン不適格MIBC患者を含むランダム化試験.
- 参加者は,外科手術後のエンフォルトゥマブ (ヴェドチン) とペムブロリズマブ (ペムブロリズマブ) を併用し,手術を受けたか,または手術のみを受けた.
- 主要エンドポイントはイベントフリー生存であり,次要エンドポイントは全生存率と病理学的完全応答を含んでいた.
主要な成果:
- 周術後のエンフォルトゥマブ・ヴェドチンとペンブロリズマブは,2年間のイベントフリー生存率 (74.7% vs. 39.4%) と全生存率 (79.7% vs. 63.1%) を有意に改善した.
- 病理学的完全応答率は,併用療法群で大幅に高かった (57.1%対8.6%).
- 併用アームのすべての参加者において有害事象が観察され,グレード3以上の有害事象は71.3%で発生しました.
結論:
- 周術のエンフォルトゥマブベドチンとペンブロリズマブは,シスプラチン不適格MIBC患者にとって,生存の有意な利点とより高い病理学的完全応答率を提供します.
- 組み合わせ治療は,この集団にとって有望な治療アプローチを示していますが,安全性の考慮は重要です.
関連する概念動画
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Urinary Tract Calculi VI: Surgical Management
616
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
616
Urinary Bladder
3.7K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
3.7K
Urinary Tract Calculi III: Medical Management
288
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
288


